Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib[...]

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani[...]

Use of ancillary studies in pediatric spitzoid neoplasms: A retrospective cohort study

Chen A, Krenitsky A, Perry SS, Tan KW, Swick BL, Anderson KR, Barry KK, Kelsey B, Carlberg VM, Coughlin CC, Craddock M, Fadzeyeva H, Ferringer[...]